ONO Pharma says Taiwan approves Opdivo perioperative regimen for resectable NSCLC
BMY•Approval based on CheckMate-77T results
The decision was based on CheckMate-77T results showing improved event-free survival, with higher pathologic complete response and major pathologic response.
Taiwan approves Opdivo perioperative use in resectable NSCLC
ONO Pharmaceutical’s Taiwan unit secured TFDA clearance on Aug. 19 for Opdivo in resectable non-small cell lung cancer.
The label covers perioperative use: neoadjuvant Opdivo with platinum-doublet chemotherapy, then surgery, then adjuvant Opdivo monotherapy.
